Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: A call to heed the mounting evidence

Clinical Infectious Diseases

Volumn 40, Issue 5, 2005, Pages 704-708

  Singh, Nina ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; GANCICLOVIR; PLACEBO; VALGANCICLOVIR;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG COST; HEART TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; META ANALYSIS; NONHUMAN; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS MUTATION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; HUMANS; ORGAN TRANSPLANTATION;

EID: 15044349747     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/427506     Document Type: Review

References (35)

1. Schooley RT, Hirsch MS, Colvin RB, et al. Association of herpesvirus infections with T-lymphocyte-subset alterations, glomerulopathy, and opportunistic infections after renal transplantation. N Engl J Med 1983; 308: 307-13.
2. Sell MS, Bale JF Jr, Giller RH. T-lymphocyte subpopulations and function during murine cytomegalovirus infection. Pediatr Res 1985; 19:583-7.
3. George MJ, Snydman DR, Werner BG, et al. The independent role of CMV as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Am J Med 1997; 103: 106-13.
4. Humar A, Gillingham KJ, Payne WD, Dunn DL, Sutherland DE, Matas AJ. Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients. Transplantation 1999; 68:1879-83.
5. Cainelli F, Vento S. Infections and solid organ transplant rejection: a cause-and-effect relationship? Lancet Infect Dis 2002; 2:539-49.
6. Lebranchu Y, Najjar A, LaKapahi P, et al. The association of increased soluble VCAM-1 levels with CMV disease in human kidney allograft recipients: CMV disease in human kidney allograft recipients. Transplant Proc 1995; 27:960.
7. Kas-Deelan AM, Harmen MC, de Maar EF, et al. Acute rejection before cytomegalovirus injection enhances von Willebrand factor and soluble VCAM-1 in blood. Kidney Int 2000; 58:2533-42.
8. Evans PC, Soin A, Wreghitt TG, Taylor CJ, Wright DGD, Alexander GJM. An association between cytomegalovirus infection and chronic rejection after liver transplantation. Transplantation 2000; 69:30-5.
9. Lemstrom K, Koskinen P, Krogerus L, Daemen M, Bruggeman C, Hayry P. Cytomegalovirus antigen expression, endothelial cell proliferation, and initial thickening in rat cardiac allografts after cytomegalovirus infection. Circulation 1995; 92:2594-604.
10. Kalil AC, Levitsky J, Lyden E, et al. Preemptive therapy (PRE) and universal prophylaxis (PRO) for cytomegalovirus (CMV) in solid organ transplant recipients (SOT): a meta-analyses [abstract 639]. In: Program and abstracts of the 42nd Annual Meeting of the Infectious Diseases Society of America (Boston). Alexandria, VA: Infectious Diseases Society of America, 2004:167.
11. Gane E, Saliba F, Valdecasas GJC, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 1997; 350:1729-33.
12. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4:611-20.
13. Limaye AP, Bakthavatsalam R, Kim HW, et al. Late-onset CMV disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2004; 78:1390-6.
14. Akalin E, Shegal V, Ames S, et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 2003; 3:731-5.
15. Park JM, Arenas JD, Fontana RJ, Lake KD. Efficacy and safety of low-dose valganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients. Am J Transplant 2004; 4:502.
16. Levitsky J, Freifeld AG, Bargenquast K, Stevens B, Kalil AC. The clinical value to quantitative polymerase chain reaction in cytomegalovirus infection after solid organ transplantation. Am J Transplant 2004; 4:339.
17. Rubin RH, Kemmerly SA, Conti D, et al. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Transpl Infect Dis 2000; 2:112-7.
18. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among solid organ transplant recipients. Lancet 2000; 356:645-9.
19. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83: 1971-9.
20. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992; 257:238-41.
21. Zeevi A, Morel P, Spichty K, et al. Clinical significance of CMV-specific T helper responses in lung transplant recipients. Hum Immunol 1998; 59:768-75.
22. Hakki M, Riddell SR, Storek J, et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood 2003; 102: 3060-7.
23. Lacey SF, Diamond DJ, Zaia JA. Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants. Biol Blood Marrow Transplant 2004; 10:433-47.
24. Wade JC, Day LM, Crowley JJ, Meyers JD. Recurrent infection with herpes simplex virus after marrow transplantation: role of the specific immune response and acyclovir treatment. J Infect Dis 1984; 149:750-6.
25. Lowance D, Neumayer H-H, Legendre M, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999; 340:1462-70.
26. Singh N, Wagener MM, Gayowski T. Lack of occurrence of late-onset CMV disease in liver transplant recipients receiving preemptive therapy with oral ganciclovir (GCV) for CMV prophylaxis [abstract V-1246]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002:439.
27. Singh N, Gayowski T, Wagener MM, Cacciarelli T. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset CMV disease. Transplantation 2005; 79:85-90.
28. Singh N. Delayed occurrence of cytomegalovirus disease in organ transplant recipients receiving antiviral prophylaxis: are we winning the battle only to lose the war? Eur J Clin Microbiol Infect Dis 2002; 21:643-6.
29. Kanj SS, Sharara AI, Clavien PA, Hamilton JD. Cytomegalovirus infection following liver transplantation: review of the literature. Clin Infect Dis 1996; 22:537-49.
30. Reusser P, Cathomas G, Attenhofer R, Tamm M, Thiel G. Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load. J Infect Dis 1999; 180:247-53.
31. Emery VC. Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 2001; 11: 83-6.
32. Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003; 101:407-14.
33. Bovin G, Goyette N, Gilbert C, et al. Absence of cytomegalovirus- resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 2004; 189:1615-8.
34. Emery VC, Griffiths PD. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci U S A 2000; 97:8039-44.
35. Boivin G, Gilbert C, Gaudreau A, Greenfield I, Sudlow R, Roberts NA. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immuno-deficiency syndrome who are receiving valganciclovir a induction and maintenance therapy for CMV retinitis. J Infect Dis 2001; 184:1598-602.